Despite a long history of incorporating steroids into silicone elastomers for drug delivery 16 applications, little is presently known about the propensity for irreversible drug binding in these 17 systems. In this study, the ability of the contraceptive progestin levonorgestrel to bind 18 chemically with hydrosilane groups in addition-cure silicone elastomers has been thoroughly 19 investigated. Cure time, cure temperature, levonorgestrel particle size, initial levonorgestrel 20 loading and silicone elastomer type were demonstrated to be key parameters impacting the 21 extent of levonorgestrel binding, each through their influence on the solubility of levonorgestrel 22 in the silicone elastomer. Understanding and overcoming this levonorgestrel binding 23 phenomenon is critical for the ongoing development of a number of drug delivery products, 24 including a multi-purpose technology vaginal ring device offering simultaneous release of 25 levonorgestrel and dapivirine -a lead candidate antiretroviral microbicide -for combination 26 HIV prevention and hormonal contraception.
Introduction
Silicone elastomers have been widely used in controlled release drug delivery applications since 29 Dzuik and Cook first demonstrated in 1966 that various steroid molecules were capable of 30 effectively permeating and releasing from silicone rubber capsules subcutaneously implanted in 31 ewes [1] . Numerous steroid-releasing silicone elastomer devices, including subdermal implants, 32 vaginal rings and intrauterine systems, have since reached market ( Table 1 ). The past ten years 33 have seen considerable interest in silicone elastomer vaginal ring technology for controlled 34 release of antiretroviral (ARV) drug molecules for prevention of sexual transmission of human 35 immunodeficiency virus (HIV) ( Table 1) Figure 1A) , a non-nucleoside reverse transcriptase inhibitor, 39 over 28 days and has already been shown to be safe and well tolerated in vivo. If successful, the 40 dapivirine ring will likely provide both further impetus and a viable technology platform for 41 development of multi-purpose prevention technologies (MPTs) aimed at combining HIV 42 prevention with prevention of unintended pregnancy and prevention/treatment of other 43 sexually transmitted infections (STIs) through use of a single formulation or drug-device 44 combination product [10] [11] [12] [13] . Many of the MPT products currently undergoing development 45 have prioritised use of levonorgestrel ( Figure 1A) as the contraceptive hormone component, 46 based on its historical record of safety and efficacy [12] [13] [14] . were processed using the supplied Waters Breeze software. Friday so as to maintain sink conditions through the following Monday. Immediately after drug sampling, the swollen slabs were removed from the dichloromethane, 197 wiped with tissue paper to remove any excess solvent, placed in a tightly closed flasks and 198 weighed (W1). These slabs were then dried overnight in a fume hood at room temperature, 199 followed by drying at 60°C for 1 h. The dry weights of the slabs were recorded (W2). The dried 200 slabs were then placed in 50 mL of n-hexane. As before, the swollen slabs were weighed (W3), 201 dried, and weighed again (W4). The amount of drug extracted, swelling ratio and total mass 202 extracted from these silicone elastomer slabs in both solvents were calculated (Equations 1 -203 4). and d90 values) for each of the four materials are also presented in Table 2 . Table 2 . In order for effective drug release to occur from a silicone elastomer vaginal ring device, 277 incorporated drug substances must permeate through the bulk of the silicone elastomer matrix.
278
This permeation process can be considered as two discrete steps -dissolution of the drug in Figures 6A and 6B, respectively) . In fact, the non-micronised levonorgestrel MED-4870 slabs 308 showed a clear trend of decreasing levonorgestrel recovery values as a function of both 309 increasing cure temperature ( Figure 5A ) and increasing cure time ( Figure 5B) . These data and 310 trends strongly support the hypothesis that levonorgestrel binding to the silicone elastomer 311 system is dependent on its solubilization in the elastomer. For the MED-4870 system, the highest recovery of levonorgestrel (66.2%) was measured for the 320 non-micronised levonorgestrel slabs prepared at the 120 °C / 10 min cure condition ( Figure 5A ).
321
This value is significantly below the range of acceptable assay values (85-115%) commonly 322 specified for a Phase 1 product. Although higher values for levonorgestrel recovery could be 323 achieved for the MED-4870 system by curing at lower temperatures, this would lead to 324 significantly increased process cycle times such that scaled manufacture would be impractical. An alternative medical grade addition-cure silicone elastomer system, DDU-4320, was selected 333 for testing based on its recommended low cure temperature characteristics. For silicone 334 elastomer slabs containing micronised levonorgestrel and prepared at 60 °C for 7 min, 335 levonorgestrel recovery was 75.6%, with values decreasing as cure temperature was increased 336 ( Figure 5C ). However, no levonorgestrel recovery was obtained for cure temperatures 120 °C 337 and above ( Figure 5C ). For the non-micronised levonorgestrel DDU-4320 samples, 338 levonorgestrel recovery values were significantly higher (87.3% at 60 °C declining to 58.5% at 339 160 °C; Figure 5C ) compared to those for micronised levonorgestrel, mimicking the trend 340 observed previously with the high temperature cure MED-4870 system. Selecting an 341 24 intermediate cure temperature of 100 °C for this DDU-4320 system, the effect of varying cure 342 time has a greater influence on the micronised levonorgestrel compared with the non-343 micronized material ( Figure 5D ). Importantly, the DDU-4320 slabs containing non-micronised 344 levonorgestrel offered levonorgestrel recovery values close to the specified range for content 345 assay / uniformity (90-110% label claim). (Table 2) . Silicone elastomer DDU-4320 slabs containing 0.4% w/w levonorgestrel were 361 prepared at 100 ˚C for 90 s for each levonorgestrel batch. As expected, the levonorgestrel 362 recovery values for these sieved levonorgestrel materials (56.7% and 55.6%; Table 2) lie   363   25 between the values for the previously tested non-micronised levonorgestrel and micronised 364 levonorgestrel (98.4% and 41.3%, respectively; Table 2) The percentage recovery of levonorgestrel from DDU-4320 silicone elastomer vaginal rings 370 cured at 90˚C for 3 min increased (55.0 -84.9%) as the loading amount of micronised 371 levonorgestrel incorporated into the device was increased from 25 to 100 and 400 mg (Table 3) . (Table 3) . These recovery values are also slightly higher than those predicted based on the 377 previous slab data ( Figure 5 ). This is likely attributed to a temperature-insulating effect for drug Figure 7B ). An entirely similar trend is also observed for the percentage 450 swelling values (in dichloromethane; Figure 7C ), adding further support to the different impact 451 of the various drug molecules on the silicone elastomer crosslinking density. Conventionally, 452 crosslinking densities in silicone elastomer systems are measured by swelling samples in hexane 453 rather than dichloromethane. Subsequent placement of the silicone elastomer slabs into 454 hexane resulted in minimal additional mass loss ( Figure 7D) , and confirmed the previous trend 455 in crosslinking density obtained with dichloromethane (compare Figures 8C and 7E ). The plot of 456 mean percentage mass extraction verses mean percentage swelling for the various silicone 457 elastomer slab formulations showed a linear positive correlation (r 2 = 0.972) ( Figure 7F ). 
